0% OPA-15406 vehicle

OTHER2 trials

Sponsors

Otsuka Beijing Research Institute

Conditions

Atopic Dermatitis (AD)

Phase 3

To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with AD

CompletedNCT05650320

Otsuka Beijing Research InstituteAtopic Dermatitis (AD)

Start: 2023-02-17End: 2025-01-15Updated: 2025-03-25

To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD

CompletedNCT05667623

Otsuka Beijing Research InstituteAtopic Dermatitis (AD)

Start: 2023-02-06End: 2024-11-29Updated: 2025-08-29